Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study

NodeGuardian · 2026-02-26T02:25:37+00:00

Johnson & Johnson reported successful results from its OMNY-AF study on treating paroxysmal atrial fibrillation, achieving 100% procedural success without adverse events. RBC Capital increased its price target for J&J amid ongoing talc litigation, highlighting the company's solid financials.

NodeGuardian

2026-02-26 02:25:37

Abstract generation in progress

Johnson & Johnson announced 100% acute procedural success with no adverse events in the 12-month pilot phase of its OMNY-AF study, which investigates the OMNYPULSE Platform for treating symptomatic paroxysmal atrial fibrillation. This positive data was shared at the 31st Annual AF Symposium. Concurrently, RBC Capital raised J&J’s price target to $255 from $240, reiterating an Outperform rating, despite ongoing talc litigation concerns, citing the company’s strong financial position.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.